D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation

D. Boral Capital LLC, a New York-based global investment bank, has demonstrated its expertise in the financial sector by serving as the exclusive placement agent for Omeros Corporation's (NASDAQ: OMER) recent $22 million registered direct offering. This transaction, which closed on July 28, 2025, involved the sale of 5,365,853 shares of common stock at $4.10 per share, marking a 14% premium to the closing price on the date of the securities purchase agreement. The offering was conducted under a 'shelf' Registration Statement on Form S-3, showcasing the strategic financial maneuvers that companies like Omeros undertake to secure funding for their operations and growth initiatives.

The significance of this offering extends beyond the immediate financial boost for Omeros Corporation. It underscores the critical role that investment banks like D. Boral Capital play in bridging the gap between companies seeking capital and investors looking for opportunities. With a track record of aggregating approximately $30 billion in capital since its inception in 2020, D. Boral Capital has established itself as a key player in the investment banking sector. This transaction not only reinforces its reputation but also highlights the confidence that companies and investors place in its ability to facilitate complex financial transactions.

For more details on D. Boral Capital's services and achievements, visit https://dboralcapital.com/. Additionally, to understand the broader context of such financial transactions and their impact on the market, https://www.InvestorWire.com offers insights into the dynamics of investment and corporate communications.

This offering is a testament to the vibrant activity in the biotech sector, where companies like Omeros are continuously seeking innovative ways to fund their research and development efforts. The successful closure of this offering, facilitated by D. Boral Capital, not only provides Omeros with the necessary capital to advance its projects but also signals to the market the potential for growth and innovation within the biotech industry.